替莫唑胺治疗术后恶性脑胶质瘤的疗效

【目的】探讨替莫唑胺（TMZ）对术后恶性脑胶质瘤进行化疗的疗效。【方法】经手术后病理确诊的恶性脑胶质瘤病人60例，随机分成实验组和对照组（各30例），分别服用替莫唑胺TMZ，200rag／（m^2·d）]和洛莫司汀CCNU，150mg／（m^2·d）]，3-5个疗程。【结果】实验组有效率、控制率（46．67％、76．，67％）均明显高于对照组（20．000，46．67％），两组差异有显著性（P〈0．05）。实验组患者1年生存率明显高于对照组，且差异均有显著性（P〈0．05）。实验组的总生存时间（11．77±2．08）个月]明显长于对照组（8．90±2．84）个月]（P〈0．05）。药物安全性评价显示，TMZ较CCNU更加安全。【结论】与CCNU相比，TMZ治疗恶性胶质瘤患者更安全、有效。

Efficacy and Adverse Reactions of Temozolomide(TMZ) in the Treatment of Patients with Malignant Gliomas after Operation

Objective]To evaluate the efficacy and adverse reactions of temozolomide（TMZ） in the treat- ment of patients with malignant gliomas after operation. Methods] Sixty patients malignant gliomas Confirmed by surgical pathology were enrolled in this study. They were randomly divided into test group（TMZ, n =30） and control group （CCNU, n =30）. All patients in two groups were administered with TMZ or CCNU for 3-5 courses of treatment. Results] The response rate was 46.67 % in test group and 20. 00% in control group, and there was statistically significant difference between two groups（ P 〈0.05）. The control rate was 76.67% in test group and 46.67% in control group, and there was significant difference between two groups（ P 〈0.05）. The 1 year survival rate were 50. 00% in test group, respectively, but they were 23.33% in control group, respectively, and there was significant difference （ P 〈0.05）. The total survival time was （11.77±2.08）m and （8.90±2.84）m in test group and control group, respectively, and there was significant difference between two groups （ P 〈0. 05）. Drug safety evaluation indicated that TMZ was safer than CCNU,